Genetically Engineered Natural Killer (NK) Cells With or Without Atezolizumab for the Treatment of Non-small Cell Lung Cancer Previously Treated With PD-1 and/or PD-L1 Immune Checkpoint Inhibitors

Inclusion Criteria:

Documented informed consent of the participant and/or legally authorized representative

Assent, when appropriate, will be obtained per institutional guidelines
Agreement to allow the use of archival tissue from diagnostic tumor biopsies
Age >= 18 years
Eastern Cooperative Oncology Group (ECOG) 0 or 1
Lung non-small cell carcinoma (NSCLC) patients with advanced, metastatic, or recurrent disease, previously treated with a PD-1 or PD-L1 immune checkpoint inhibitor, either as single agent or in combination with chemotherapy or other immunotherapy or experimental agents
Radiographically demonstrable tumor progression treatment on or after therapy with a PD-1/PD-L1 immune checkpoint inhibitor
Preserved organ function and recovery of prior drug related toxicities (except alopecia or grade 2 anemia) to grade 1 or better
No cytotoxic chemotherapy or immunotherapy over the three weeks prior to lymphodepletion
Histologically confirmed non-small cell lung cancer
Measurable disease as per Response Evaluation Criteria in Solid Tumors (RECIST) criteria 1.1
Fully recovered from the acute toxic effects (except alopecia) to =< grade 1 to prior anti-cancer therapy
Absolute neutrophil count (ANC) >= 1,500/mm^3
Hemoglobin (Hgb) >= 8 g/dl
Platelets >= 100,000/mm^3
Total bilirubin =< 1.5 x upper limit of normal (ULN)
Aspartate aminotransferase (AST) =< 1.5 x ULN
Alanine aminotransferase (ALT) =< 1.5 x ULN
Alkaline phosphatase (AP) =< 1.5 x ULN
Creatinine clearance of >= 60 mL/min per 24-hour urine test or the Cockcroft-Gault formula
If not receiving anticoagulants: International normalized ratio (INR) OR prothrombin (PT) =< 1.5 x ULN
If on anticoagulant therapy: PT must be within therapeutic range of intended use of anticoagulants

Seronegative for human immunodeficiency virus (HIV) antigen (Ag)/antibody (Ab) combo, hepatitis C virus (HCV), active hepatitis B virus (HBV) (surface antigen negative)

If positive, hepatitis C ribonucleic acid (RNA) quantitation must be performed
Women of childbearing potential (WOCBP): Negative urine or serum pregnancy test. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required

Agreement by females and males of childbearing potential to use an effective method of birth control or abstain from heterosexual activity for the course of the study through at least 06 months after the last dose of protocol therapy

Childbearing potential defined as not being surgically sterilized (men and women) or have not been free from menses for > 1 year (women only)

Exclusion Criteria:

Autologous stem cell transplant within 1 year prior to day 1 of protocol therapy
Chemotherapy, radiation therapy, biological therapy, immunotherapy within 21 days prior to day 1 of protocol therapy
History of allergic reactions attributed to compounds of similar chemical or biologic composition to study agent
Active diarrhea
Clinically significant uncontrolled illness
Active infection requiring antibiotics
Known history and/or positive serology for immunodeficiency virus (HIV) or hepatitis B or hepatitis C infection
Diagnosis of Gilbert's disease
Other active malignancy
Females only: Pregnant or breastfeeding
Severe (grade 3 or higher) immune related adverse events during prior PD-1 inhibitor treatment
Any other condition that would, in the Investigator's judgment, contraindicate the patient's participation in the clinical study due to safety concerns with clinical study procedures
Concomitant use of other investigational agents
Patients with EGFR mutations or ALK translocations in their tumors, unless treatment with the indicated tyrosine kinase inhibitor has failed
Active brain metastases. Previously treated brain metastasis must demonstrate stability on subsequent magnetic resonance imaging (MRI) scans
Prospective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility/logistics)